RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/SHA-384/AB3DBA5F45D521D893F2EA464AD6B5C054D833A9FFA700B7F71F2FA68F9633F9C856EF2633E78EAE91B4661D6718588Ahttp://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/AB3DBA5F45D521D893F2EA464AD6B5C054D833A9FFA700B7F71F2FA68F9633F9C856EF2633E78EAE91B4661D6718588Ahttp://www.w3.org/2000/01/rdf-schema#comment"The aim of this study was to assess clinical utility of the anti-Domain 1 B2GP1 antibodies in the diagnosis and risk stratification of antiphospholipid syndrome. Anti-Domain 1 test does not add accuracy in predicting Antiphospholipid syndrome thrombotic complications on the top of accuracy offered by classic tests."xsd:string
http://purl.uniprot.org/uniprot/#_47A817BA0B8A7D26993EB75FEC01179DDBD80083D1E8D545662DC379027E575389BF7948F2BB1BB92227FBFA17EE1461http://www.w3.org/1999/02/22-rdf-syntax-ns#subjecthttp://purl.uniprot.org/SHA-384/AB3DBA5F45D521D893F2EA464AD6B5C054D833A9FFA700B7F71F2FA68F9633F9C856EF2633E78EAE91B4661D6718588A
http://purl.uniprot.org/uniprot/P02749http://purl.uniprot.org/core/mappedAnnotationhttp://purl.uniprot.org/SHA-384/AB3DBA5F45D521D893F2EA464AD6B5C054D833A9FFA700B7F71F2FA68F9633F9C856EF2633E78EAE91B4661D6718588A
http://purl.uniprot.org/uniprot/#_P02749-mappedCitation-28363116http://purl.uniprot.org/core/mappedAnnotationhttp://purl.uniprot.org/SHA-384/AB3DBA5F45D521D893F2EA464AD6B5C054D833A9FFA700B7F71F2FA68F9633F9C856EF2633E78EAE91B4661D6718588A